International Cooperation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Institute, the Second Military Medical University, 225 Changhai Road, Shanghai, 200433, PR China.
BMC Cancer. 2011 Jun 25;11:271. doi: 10.1186/1471-2407-11-271.
Our previous studies showed that ZBTB20, a new BTB/POZ-domain gene, could negatively regulate α feto-protein and other liver-specific genes, concerning such as bio-transformation, glucose metabolism and the regulation of the somatotropic hormonal axis. The aim of this study is to determine the potential clinical implications of ZBTB20 in hepatocellular carcinoma (HCC).
Quantitative real-time RT-PCR and Western blot analyses were used to detect expression levels of ZBTB20 in 50 paired HCC tumorous and nontumorous tissues and in 20 normal liver tissues. Moreover, expression of ZBTB20 was assessed by immunohistochemistry of paired tumor and peritumoral liver tissue from 102 patients who had undergone hepatectomy for histologically proven HCC. And its relationship with clinicopathological parameters and prognosis was investigated.
Both messenger RNA and protein expression levels of ZBTB20 were elevated significantly in HCC tissues compared with the paired non-tumor tissues and normal liver tissues. Overexpressed ZBTB20 protein in HCC was significantly associated with vein invasion (P=0.016). Importantly, the recurrence or metastasis rates of HCCs with higher ZBTB20 expression were markedly greater than those of HCCs with lower expression (P=0.003, P=0.00015, respectively). Univariate and multivariate analyses revealed that ZBTB20 overexpression was an independent prognostic factor for HCC. The disease-free survival period and over-all survival period in patients with overexpressed ZBTB20 in HCC was significantly reduced.
The expression of ZBTB20 is increased in HCC and associated with poor prognosis in patients with HCC, implicating ZBTB20 as a candidate prognostic marker in HCC.
我们之前的研究表明,ZBTB20 是一种新的 BTB/POZ 结构域基因,可负向调节α 胎蛋白和其他肝脏特异性基因,涉及生物转化、糖代谢和生长激素轴的调节。本研究旨在确定 ZBTB20 在肝细胞癌(HCC)中的潜在临床意义。
采用实时定量 RT-PCR 和 Western blot 分析检测 50 对 HCC 肿瘤组织和非肿瘤组织及 20 例正常肝组织中 ZBTB20 的表达水平。此外,通过对 102 例接受肝切除术治疗组织学证实的 HCC 患者的配对肿瘤和肿瘤周围肝组织进行免疫组织化学检测,评估 ZBTB20 的表达。并探讨其与临床病理参数和预后的关系。
与配对非肿瘤组织和正常肝组织相比,ZBTB20 的信使 RNA 和蛋白表达水平在 HCC 组织中均显著升高。在 HCC 中,过表达的 ZBTB20 蛋白与静脉侵犯显著相关(P=0.016)。重要的是,ZBTB20 表达较高的 HCC 的复发或转移率明显高于 ZBTB20 表达较低的 HCC(P=0.003,P=0.00015,分别)。单因素和多因素分析表明,ZBTB20 过表达是 HCC 的独立预后因素。ZBTB20 在 HCC 中过表达的患者无病生存期和总生存期明显缩短。
ZBTB20 在 HCC 中表达增加,与 HCC 患者的不良预后相关,提示 ZBTB20 可作为 HCC 的候选预后标志物。